MaxCyte® GT™ Transfection System by MaxCyte

It enables the discovery, development and manufacturing of innovative therapeutic products for a wide range of diseases by overcoming the existing obstacles of cell therapy with its high-volume, rapid and inherently safe technology. The MaxCyte GT uses simple, computer-controlled protocols to transfect up to 1 x 1010 cells in less than 30 minutes and is capable of loading multiple molecules (DNA, mRNA, siRNA, proteins, and small molecules) into autologous or allogenic immune, stem/progenitor or somatic cells.

The system is pre-configured with protocols optimized for specific cell types and applications. This cell processing system has received Master File designation with the CBER Division of the U.S. FDA and has been cleared by NIH's RAC and Health Canada.


Features:

• Fully scalable, able to transfect 5x105 cells in seconds up to 1x1010 cells in < 30 minutes
• CE marked platform for automated, robust, rapid, scalable, cGMPcompliant, closed processing for Cell Therapy Development
• Obtain high viability and recovery of cells with augmented biological activity for development of more effective cellular therapeutics
• Accelerate pre-clinical development and product evaluations in clinical trials by cross-referencing MaxCyte's FDA Master File

Applications:

• Ex vivo Cell Therapy
• Immunotherapy
• Regenerative Medicine
• Viral Vector Manufacturing